Breast Imaging

Should You Order Ultrasound for Axillary Staging in Large, Node-Positive Breast Cancer?

·
Should You Order Ultrasound for Axillary Staging in Large, Node-Positive Breast Cancer?

A 58-year-old woman presents to your clinic for follow-up. A week ago, a diagnostic mammogram and subsequent biopsy confirmed a 3 cm invasive ductal carcinoma in her left breast. On your physical exam today, you palpate a firm, mobile 1.5 cm lymph node in her left axilla, consistent with clinical N1 disease. The multidisciplinary tumor board meets in two days to discuss her case and formulate a treatment plan. Your immediate task is to order the correct initial imaging study to evaluate her axilla, providing crucial information for staging and surgical planning. This article details the American College of Radiology (ACR) guided workflow for this specific clinical scenario, where an axillary ultrasound is designated as Usually Appropriate.

Who Fits This Clinical Scenario for Axillary Imaging?

This guidance applies to a specific patient population: a female with a newly diagnosed breast cancer where the primary tumor is greater than 2 cm and there is clinical suspicion of axillary lymph node involvement. “Clinical node-positive” status can be determined by a palpable axillary lump on physical examination or suspicious-appearing nodes seen on the initial diagnostic mammogram or digital breast tomosynthesis (DBT).

The key elements defining this scenario are:

  • New Diagnosis: The patient has a recent tissue diagnosis of breast cancer.
  • Tumor Size: The primary breast tumor measures > 2 cm.
  • Clinical Nodal Status: There is a clinical suspicion for axillary metastasis.
  • Timing: This is the initial imaging workup of the axilla, performed after the breast cancer diagnosis but before any treatment (e.g., surgery or neoadjuvant chemotherapy) has begun.

It is critical to distinguish this from similar but distinct clinical situations. This workflow does not apply to patients with smaller tumors (≤ 2 cm) and clinically negative nodes, who may undergo sentinel lymph node biopsy without preoperative axillary imaging. It also differs from the workup of a patient presenting with a new palpable axillary lump but no known primary breast cancer, which follows a different diagnostic algorithm. Finally, patients already undergoing neoadjuvant chemotherapy require a separate imaging approach to assess treatment response.

What Diagnoses Are You Working Up in This Scenario?

In this context, the primary diagnosis of breast cancer is already established. The imaging goal is not to find a new diagnosis but to accurately stage the known disease by evaluating the axillary lymph nodes. The “differential” here is a focused assessment of the extent of nodal involvement, which directly impacts prognosis and treatment decisions.

The primary objective is to confirm and characterize axillary nodal metastasis. The presence of a clinically suspicious node requires pathologic confirmation. Imaging helps determine if the palpable node has morphologic features of malignancy (e.g., cortical thickening, loss of the fatty hilum, rounded shape) and, crucially, identifies a target for biopsy. This step is vital for converting a clinical suspicion into a definitive pathologic N-stage.

A secondary goal is to identify additional, non-palpable suspicious nodes. A comprehensive ultrasound survey of the entire axilla can reveal other involved nodes that were not clinically apparent. Discovering multiple involved nodes can upstage the patient and significantly alter the management plan, potentially shifting the recommendation from upfront surgery to neoadjuvant chemotherapy.

Finally, imaging serves to guide intervention. The most important function of axillary ultrasound in this setting is to facilitate a minimally invasive tissue diagnosis. By providing real-time visualization, it enables a radiologist to perform a fine-needle aspiration (FNA) or core needle biopsy of the most suspicious-looking node, providing the definitive evidence needed for the treatment plan.

Why Is Axillary Ultrasound the Recommended First Study for This Presentation?

The ACR designates axillary ultrasound (US) as Usually Appropriate for this scenario because it is the most direct, effective, and safest tool to answer the primary clinical question: is the axilla pathologically positive? Its value lies in its unique combination of high-resolution imaging and its ability to guide immediate biopsy.

Axillary US offers excellent spatial resolution, allowing for detailed morphologic assessment of lymph nodes. It can reliably identify features suggestive of metastasis, such as cortical thickness greater than 3 mm, effacement or absence of the fatty hilum, and a rounded rather than oval shape. This diagnostic capability is paired with its primary advantage: facilitating image-guided sampling. A positive US finding can be immediately followed by a US-guided FNA or core biopsy in the same appointment. This provides a rapid, minimally invasive pathway to a definitive pathologic diagnosis, which is essential for accurate staging and planning treatment with the multidisciplinary team.

From a safety and practicality standpoint, US is ideal. It involves no ionizing radiation (0 mSv) and does not require intravenous contrast, avoiding potential risks of allergic reaction or contrast-induced nephropathy. It is also widely available and less costly than other cross-sectional imaging modalities.

Alternative studies are rated lower for this specific initial task:

  • MRI breast without and with IV contrast is rated May be appropriate. While breast MRI is excellent for evaluating the extent of disease within the breast, it is not the primary tool for axillary nodal characterization. It is less specific than targeted US for nodal morphology and does not allow for concurrent biopsy.
  • FDG-PET/CT skull base to mid-thigh is also rated May be appropriate. This is a powerful tool for systemic staging to detect distant metastatic disease. However, it is not the first-line test for initial axillary evaluation due to its higher radiation dose (☢☢☢☢ 10-30 mSv), lower spatial resolution for nodal detail compared to US, and higher cost. It is often considered a downstream study after the axilla is proven to be node-positive.

What’s Next After an Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound and any subsequent biopsy create a clear decision tree for patient management. The goal is to move from clinical suspicion to pathologic certainty, which then dictates surgical and systemic therapy.

If the ultrasound identifies suspicious nodes and the US-guided biopsy is POSITIVE for metastatic carcinoma:

The patient is now confirmed to have pathologic N1 (or greater) disease. This confirmation is a critical branch point. The patient may be a candidate for neoadjuvant (preoperative) chemotherapy, especially with a large primary tumor and positive nodes. This approach can downstage both the breast and axilla, potentially allowing for less extensive surgery later. Alternatively, if proceeding to upfront surgery, the patient will typically require an axillary lymph node dissection (ALND) rather than a sentinel lymph node biopsy (SLNB).

If the ultrasound identifies suspicious nodes but the US-guided biopsy is NEGATIVE:

This result introduces uncertainty. A negative FNA or core biopsy can represent a false negative (sampling error). In this situation, the next step is typically a sentinel lymph node biopsy at the time of surgery. The clinically and sonographically suspicious node that was biopsied is often marked with a clip, allowing the surgeon to remove it specifically (a targeted axillary dissection, or TAD) along with the other sentinel nodes for a more thorough pathologic evaluation.

If the ultrasound is completely NEGATIVE (no suspicious nodes identified):

Despite the clinical suspicion, a completely normal-appearing axilla on a high-quality ultrasound is reassuring. However, given the high pre-test probability (large tumor, clinically positive exam), this patient would still proceed to surgical staging with a sentinel lymph node biopsy to pathologically confirm the negative status of the axilla.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for clinically node-positive breast cancer requires careful attention to detail to avoid common missteps. A primary pitfall is proceeding directly to surgery without preoperative tissue confirmation of a suspicious axillary node. Obtaining a biopsy via US guidance provides crucial staging information that can fundamentally change the treatment plan, such as indicating a need for neoadjuvant chemotherapy.

Another error is ordering a systemic staging study like a PET/CT before the axillary US. The US with biopsy is the most direct and efficient way to confirm nodal status. The decision to order a PET/CT is often dependent on the result of the axillary biopsy, making it a downstream, not an initial, step.

Finally, ensure the ultrasound order is specific. It should be for a “diagnostic axillary ultrasound with possible image-guided biopsy” to empower the radiology department to complete the workup in a single session. If the results of imaging and biopsy are discordant with the clinical exam, escalation to a multidisciplinary tumor board discussion is essential to determine the next best step.

Related ACR Topics and Tools

This article focuses on a single, specific clinical scenario. For a comprehensive overview of all clinical variants related to axillary imaging, from palpable lumps to post-treatment follow-up, please consult our parent guide. Additional GigHz tools can help you apply these principles in your daily practice.

Frequently Asked Questions

Why not order a breast MRI to evaluate the axilla at the same time?

While a breast MRI (rated ‘May be appropriate’) does visualize the axilla, its primary strength is assessing the extent of disease within the breast itself. For detailed evaluation of lymph node morphology and, most importantly, to guide a biopsy for pathologic confirmation, a targeted axillary ultrasound is superior. The US allows for immediate tissue sampling, which is the critical next step in this scenario.

If the patient is likely to get a PET/CT for staging, can I just start with that?

Starting with a PET/CT is generally not recommended for the initial axillary evaluation. An axillary ultrasound is faster, less expensive, involves no radiation, and offers better spatial resolution for guiding a biopsy. The decision to perform a PET/CT for systemic staging is often made *after* the axillary ultrasound and biopsy confirm node-positive disease, as this finding increases the risk of distant metastases.

What if the ultrasound-guided biopsy of a suspicious node comes back negative?

This is a key clinical challenge, as it could be a false negative due to sampling error. In this case, the patient typically proceeds to surgery with a sentinel lymph node biopsy (SLNB). Often, the sonographically suspicious node that was biopsied is marked with a clip, allowing the surgeon to perform a targeted axillary dissection (TAD) by removing that specific node along with the other sentinel nodes for a more accurate pathologic assessment.

Does this guidance change if the tumor is smaller than 2 cm but still clinically node-positive?

Yes, the workflow is similar. The ACR addresses this in a separate clinical variant (‘Newly diagnosed breast cancer, 2 cm or less, with clinical node-positive’). Axillary ultrasound is also ‘Usually Appropriate’ in that scenario for the same reasons: to confirm the suspicious node with a biopsy before definitive treatment planning.

Is an axillary ultrasound still necessary if the patient is definitely going to get neoadjuvant chemotherapy?

Yes, it is arguably even more critical. Confirming axillary metastasis with a pre-treatment biopsy establishes the patient’s initial pathologic N-stage. This is the baseline against which treatment response will be measured. Placing a clip in the biopsied positive node before starting chemotherapy is also standard practice, as it allows for targeted surgical removal of that node after treatment (targeted axillary dissection).

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026